UNSPSC 51362506: Zopiclone

This classification denotes a sedative and hypnotic with the molecular formula C17H17ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03A5ORL08Q, chemically known as 4-methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5h-pyrrolo(3,4-b)pyrazin-5-one but generally known as zopiclone, which bears US NIH Compound Identifier 5735. European Medicines Agency schedules Zopiclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00188MIG.

UNSPSC 51362506 Zopiclone is a Commodity code nominally covering the sedative-hypnotic medication zopiclone; however, recent state and local procurement activity tagged under this code does not reflect zopiclone purchases. Instead, opportunities solicited under this code involve broader pharmaceutical procurement — generics, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs — suggesting either persistent miscoding by issuing bodies or a vendor-management data artifact in the procurement system. The actual work being solicited spans generic multi-source pharmaceuticals, opioid-reversal agents, drug deactivation systems, and pharmacy benefit program restructuring across health departments, cooperative purchasing alliances, and county health systems.

Recent activity shows a mix of issuing bodies: the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering on behalf of multiple state and local government facilities across Minnesota and Oregon; the Texas Health and Human Services Commission pursuing pharmacy benefit innovation; and Seminole County, Florida procuring naloxone and drug deactivation systems through community health initiatives. The Minnesota RFP for generic multi-source pharmaceuticals and OTC products, solicited by MMCAP with a response deadline of March 26, 2026, and the Seminole County IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023) represent the most active recent opportunities. The Texas RFI posted April 3, 2026, reflects exploratory procurement for direct-to-manufacturer prescription channels rather than a binding competitive solicitation. Geographic concentration appears light across Florida, Minnesota (with participation from Oregon), and Texas; no single jurisdiction dominates the recent pipeline. Vendors should verify proper code alignment before pursuing — the mismatch between the nominal code scope and active solicitations suggests either systematic recoding of pharmaceutical procurements into this category or incomplete taxonomy mapping by state and local systems.